Paragon spins out ninth biotech, sending cardiopulmonary drugs to Alaunos
Paragon Labs has created a ninth company, using a reverse merger model that it’s honed over the past four years to send Velaris Therapeutics straight onto the public markets. Velaris completed a transaction on Tuesday ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.